The sensitized pediatric heart transplant candidate: Causes, consequences, and treatment options

Pediatric Transplantation

Volumn 9, Issue 2, 2005, Pages 208-214

  Shaddy, Robert E ^a,b   Fuller, Thomas C ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

Author keywords

HLA antigens; Pediatric; Transplantation

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HLA ANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ANTIBODY PRODUCTION; CARDIAC GRAFT REJECTION; HEART GRAFT; HEMORRHAGIC CYSTITIS; HUMAN; INFECTION; MORBIDITY; MORTALITY; NAUSEA; REVIEW; SENSITIZATION; TREATMENT OUTCOME; VOMITING;

ANTIBODIES, MONOCLONAL; CHILD; CYCLOPHOSPHAMIDE; CYTOTOXICITY, IMMUNOLOGIC; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; PLASMAPHERESIS;

EID: 16444378996     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2005.00262.x     Document Type: Review

References (57)

1. JOHN R, LIETZ K, BURKE E, et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 1999: 100: II229-II235.
2. MCKENNA DH Jr, EASTLUND T, SEGALL M, NOREEN HJ, PARK S. HLA alloimmunization in patients requiring ventricular assist device support. J Heart Lung Transplant 2002: 21: 1218-1224.
3. GEBEL HM, BRAY RA. Sensitization and sensitivity: defining the unsensitized patient. Transplantation 2000: 69: 1370-1374.
4. PRZYBYLOWSKI P, BALOGNA M, RADOVANCEVIC B, et al. The role of flow cytometry-detected IgG and IgM anti-donor antibodies in cardiac allograft recipients. Transplantation 1999: 67: 258-262.
5. BISHAY ES, COOK DJ, STARLING RC, et al. The clinical significance of flow cytometry crossmatching in heart transplantation. Eur J Cardiothorac Surg 2000: 17: 362-369.
6. SCORNIK JC, PFAFF WW, HOWARD RJ, et al. Increased anti-body responsiveness to blood transfusions in pediatric patients. Transplantation 1994: 58: 1361-1365.
7. BRAND A. Immunological aspects of blood transfusions. Transpl Immunol 2002: 10: 183-190.
8. PETRANYI GG, RETI M, HARSANYI V, SZABO J. Immunologic consequences of blood transfusion and their clinical manifestations. Int Arch Allergy Immunol 1997: 114: 303-315.
9. MCKENNA RM, TAKEMOTO SK, TERASAKI PI. Anti-HLA antibodies after solid organ transplantation. Transplantation 2000: 69: 319-326.
10. SHADDY RE, HUNTER DD, OSBORN KA, et al. Prospective analysis of HLA immunogenicity of cryopreserved valved allografts used in pediatric heart surgery. Circulation 1996: 94: 1063-1067.
11. BREINHOLT JP III, HAWKINS JA, LAMBERT LM, FULLER TC, PROFAIZER T, SHADDY RE. A prospective analysis of the immunogenicity of cryopreserved nonvalved allografts used in pediatric heart surgery. Circulation 2000: 102: III179-III182.
12. HAWKINS JA, BREINHOLT JP, LAMBERT LM, et al. Class I and class II anti-HLA antibodies after implantation of cryopreserved allograft material in pediatric patients. J Thorac Cardiovasc Surg 2000: 119: 324-330.
13. SHADDY RE, THOMPSON DD, OSBORNE KA, HAWKINS JA, FULLER TC. Persistence of human leukocyte antigen (HLA) antibodies after one year in children receiving cryopreserved valved allografts. Am J Cardiol 1997: 80: 358-359.
14. LOPEZ-CEPERO M, SANDERS CE, BUGGS J, BOWERS V. Sensitization of renal transplant candidates by cryopreserved cadaveric venous or arterial allografts. Transplantation 2002: 73: 817-819.
15. SHADDY RE, FULLER TC, ANDERSON JB, et al. Mycophenolic mofetil reduces the HLA antibody response of children to valved allograft implantation. Ann Thorac Surg 2004: 77: 1734-1739.
16. HOOPER DK, HAWKINS JA, FULLER TC, PROFAIZER T, SHADDY RE. Prospective follow-up of panel reactive antibodies in children 5-Years following implantation of cryopresaerved allografts. J Heart Lung Transplant 2004: 23: S168.
17. TAMBUR AR, BRAY RA, TAKEMOTO SK, et al. Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejection. Transplantation 2000: 70: 1055-1059.
18. GORDON RD, FUNG JJ, MARKUS B, et al. The antibody crossmatch in liver transplantation. Surgery 1986: 100: 705-715.
19. SAIDMAN SL, DUQUESNOY RJ, DEMETRIS AJ, et al. Combined liver-kidney transplantation and the effect of preformed lymphocytotoxic antibodies. Transpl Immunol 1994: 2: 61-67.
20. SMITH JD, DANSKINE AJ, LAYLOR RM, ROSE ML, YACOUB MH. The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heart and heart-lung transplantation. Transpl Immunol 1993: 1: 60-65.
21. LAVEE J, KORMOS RL, DUQUESNOY RJ, et al. Influence of panel-reactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation. J Heart Lung Transplant 1991: 10: 921-929; discussion 929-930.
22. ITESCU S, TUNG TC, BURKE EM, et al. Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation. Circulation 1998: 98: 786-793.
23. KOBASHIGAWA JA, SABAD A, DRINKWATER D, et al. Pretransplant panel reactive-antibody screens. Are they truly a marker for poor outcome after cardiac transplantation? Circulation 1996: 94: II294-II297.
24. TURKA LA, GOGUEN JE, GAGNE JE, MILFORD EL. Presensitization and the renal allograft recipient. Transplantation 1989: 47: 234-240.
25. FULLER TC, FORBES JB, DELMONICO FL. Renal transplantation with a positive historical donor crossmatch. Transplant Proc 1985: 17: 113-114.
26. MAHLE WT, NAFTEL DC, RUSCONI P, EDENS RE, SHADDY RE, GROUP PHTS. Panel-reactive antibody cross-reactivity and outcomes in the Pediatric Heart Transplant Study Group. J Heart Lung Transplant 2004: 23: S167.
27. WEST LJ, POLLOCK-BARZIV SM, DIPCHAND AI, et al. ABO-incompatible heart transplantation in infants. N Engl J Med 2001: 344: 793-800.
28. GLOOR JM, LAGER DJ, MOORE SB, et al. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation 2003: 75: 971-977.
29. ANDERSON CB, TYLER JD, SICARD GA, ANDERMAN CK, RODEY GE, ETHEREDGE EE. Pretreatment of renal allograft recipients with immunosuppression and donor-specific blood. Transplantation 1984: 38: 664-668.
30. ELKINS RC, LANE MM, CAPPS SB, MCCUE C, DAWSON PE. Humoral immune response to allograft valve tissue pretreated with an antigen reduction process. Semin Thorac Cardiovasc Surg 2001: 13: 82-86.
31. HAWKINS JA, HILLMAN ND, LAMBERT LM, et al. Immunogenicity of decellularized cryopreserved allografts in pediatric cardiac surgery: comparison with standard cryopreserved allografts. J Thorac Cardiovasc Surg 2003: 126: 247-252; discussion 252-253.
32. MADDEN R, LIPKOWITZ G, BENEDETTO B, KURBANOV A, MILLER M, BOW L. Decellularized cadaver vein allografts used for hemodialysis access do not cause allosensitization or preclude kidney transplantation. Am J Kidney Dis 2002: 40: 1240-1243.
33. STEINHOFF G, STOCK U, KARIM N, et al. Tissue engineering of pulmonary heart valves on allogenic acellular matrix conduits: in vivo restoration of valve tissue. Circulation 2000: 102: III50-III55.
34. SCHMITZ-RIXEN T, MEGERMAN J, COLVIN RB, WILLIAMS AM, ABBOTT WM. Immunosuppressive treatment of aortic allografts. J Vasc Surg 1988: 7: 82-92.
35. WAGNER E, ROY R, MAROIS Y, DOUVILLE Y, GUIDOIN R. Fresh venous allografts in peripheral arterial reconstruction in dogs. Effects of histocompatibility and of short-term immunosuppression with cyclosporine A and mycophenolate mofetil. J Thorac Cardiovasc Surg 1995: 110: 1732-1744.
36. VISCHJAGER M, VAN GULIK TM, DE KLEINE RH, et al. Experimental arterial allografting under low and therapeutic dosages of cyclosporine for immunosuppression. Transplantation 1996: 61: 1138-1142.
37. SHADDY RE, LAMBERT LM, FULLER TC, et al. Prospective randomized trial of azathioprine in cryopreserved valved allografts grafts in children. Ann Thorac Surg 2001: 71: 43-47; discussion 47-48.
38. SHADDY RE, FULLER TC, ANDERSON JB, et al. Mycophenolic mofetil reduces the HLA antibody response of children to valved allograft. Ann Thorac Surg 2004: 77: 1734-1739.
39. ENSLEY RD, BRISTOW MR, OLSEN SL, et al. The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation 1993: 56: 75-82.
40. ROSE EA, PEPINO P, BARR ML, et al. Relation of HLA antibodies and graft atherosclerosis in human cardiac allograft recipients. J Heart Lung Transplant 1992: 11: S120-S123.
41. LIETZ K, JOHN R, SCHUSTER M, et al. Mycophenolate mofetil reduces anti-HLA antibody production and cellular rejection in heart transplant recipients. Transplant Proc 2002: 34: 1828-1829.
42. WEIGEL G, GRIESMACHER A, KARIMI A, ZUCKERMANN AO, GRIMM M, MUELLER MM. Effect of mycophenolate mofetil therapy on lymphocyte activation in heart transplant recipients. J Heart Lung Transplant 2002: 21: 1074-1079.
43. SCHMID C, GARRITSEN HS, KELSCH R, et al. Suppression of panel-reactive antibodies by treatment with mycophenolate mofetil. Thorac Cardiovasc Surg 1998: 46: 161-162.
44. ITESCU S, BURKE E, LIETZ K, et al. Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients. Circulation 2002: 105; 1214-1219.
45. BRODSKY RA, JONES RJ. High-dose cyclophosphamide in aplastic anaemia. Lancet 2001: 357: 1128-1129.
46. KAZATCHKINE MD, KAVERI SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001: 345: 747-755.
47. TYAN DB, LI VA, ZER L, TRENTO A, JORDAN SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994: 57: 553-562.
48. MCINTYRE JA, HIGGINS N, BRITTON R, et al. Utilization of intravenous immunoglobulin to ameliorate alloantibodies in a highly sensitized patient with a cardiac assist device awaiting heart transplantation. Fluorescence-activated cell sorter analysis. Transplantation 1996: 62; 691-693.
49. DE MARCO T, DAMON LE, COLOMBE B, KEITH F, CHATTERJEE K, GAROVOY MR. Successful immunomodulation with intravenous gamma globulin and cyclophosphamide in an alloimmunized heart transplant recipient. J Heart Lung Transplant 1997: 16: 360-365.
50. GLOTZ D, ANTOINE C, JULIA P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002: 2: 758-760.
51. MONTGOMERY RA, ZACHARY AA, RACUSEN LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000: 70: 887-895.
52. PISANI BA, MULLEN GM, MALINOWSKA K, et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant 1999: 18: 701-706.
53. IBRAHIM J, BLUME E, PHELAN D, LUBLIN CE, CANTER CE. Successful cardiac transplantation of pre-sensitized children without a prospective crossmatch: preliminary results. J Heart Lung Transplant 1999: 18: 83.
54. STASI R, PAGANO A, STIPA E, AMADORI S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001: 98: 952-957.
55. SAWADA T, FUCHINOUE S, TERAOKA S. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation 2002: 74: 1207-1210.
56. ARANDA JM JR, SCORNIK JC, NORMANN SJ, et al. Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. Transplantation 2002: 73: 907-910.
57. VIEIRA CA, AGARWAL A, BOOK BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation. Transplantation 2004: 77: 542-548.